Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
36
FDA:29
NMPA:7
Drug Approvals
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20171062
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20150419
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20150431
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字J20140167
- Approval Date
- Jul 31, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20150431
- Approval Date
- May 22, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20171062
- Approval Date
- May 22, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20150419
- Approval Date
- May 22, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)No trials found
News
Shanghai Henlius Biotech Receives FDA Approval for Two Denosumab Biosimilars for Osteoporosis Treatment
Shanghai Henlius Biotech has received FDA approval for two denosumab biosimilars, BILDYOS and BILPREVDA, marking the company's sixth overseas product approval.
Bio-Thera Solutions Initiates Phase 3 Trial for BAT8006 ADC in Platinum-Resistant Ovarian Cancer
Bio-Thera Solutions has dosed the first patient in a pivotal phase 3 trial for BAT8006, an antibody-drug conjugate targeting folate receptor α for platinum-resistant ovarian cancer treatment.